Počet záznamů: 1
Advances in Chemical Biology
- 1.
SYSNO ASEP 0502886 Druh ASEP M - Kapitola v monografii Zařazení RIV C - Kapitola v knize Název PPM1D as a driver and pharmacological target in clonal hematopoiesis Tvůrce(i) Macůrek, Libor (UMG-J) RID, ORCID Zdroj.dok. Advances in Chemical Biology. - Praha : OPTIO CZ, 2019 / Bartůněk Petr - ISBN 978-80-88011-03-3 Rozsah stran s. 32-39 Poč.str. 7 s. Poč.výt. 50 Poč.str.knihy 210 Forma vydání Tištěná - P Jazyk dok. eng - angličtina Země vyd. CZ - Česká republika Klíč. slova cancer ; phosphatase ; DNA damage response ; inhibitor ; clonal hematopoiesis Vědní obor RIV EB - Genetika a molekulární biologie Obor OECD Cell biology CEP LO1220 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy Institucionální podpora UMG-J - RVO:68378050 Anotace Chemotherapy or radiotherapy cause genotoxic stress that kills cancer cells and ideally only tolerable DNA damage to the neighboring healthy tissues. Cell fate after exposure to genotoxic stress is determined by the tumor suppressor p53 that controls transcription of both pro-survival and pro-apoptotic genes. Depending on the DNA damage load, cells activate the cell cycle checkpoint arrest or die through programmed cell death. Protein phosphatase 2C delta (referred to as WIP1) is a negative regulator of p53 and has been proposed as potential pharmaceutical target. Recently, mutations in PPM1D were observed in patients that developed secondary cancer after receiving a chemotherapy. This review will discuss the role of PPM1D in development of the secondary cancers as well as potential use of small-molecule inhibitors as prevention to causing these adverse effects of chemotherapy. Pracoviště Ústav molekulární genetiky Kontakt Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Rok sběru 2019
Počet záznamů: 1